Prevalence of hepatitis C virus and HIV infection among injection drug users in two Mexican cities bordering the US

被引:63
|
作者
White, Emily Faye
Garfein, Richard S.
Brouwer, Kimberly C.
Lozada, Remedios
Ramos, Rebeca
Firestone-Cruz, Michelle
Perez, Saida G.
Magis-Rodriguez, Carlos
Conde-Glez, Carlos J.
Strathdee, Steffanie A.
机构
[1] Univ Calif San Diego, San Diego Sch Med, Dept Family & Prevent Med, Div Int Hlth & Cross Cultural Med, La Jolla, CA 92093 USA
[2] Patronato COMUSIDA, Tijuana, Baja California, Mexico
[3] US Mexico Border Hlth Assoc, El Paso, TX USA
[4] Ctr Nacl Prevent & Control VIH SIDA, CENSIDA, Mexico City, DF, Mexico
[5] Inst Nacl Salud Publ, Cuernavaca, Morelos, Mexico
来源
SALUD PUBLICA DE MEXICO | 2007年 / 49卷 / 03期
关键词
hepatitis C virus; human immunodeficiency virus; injection drug use; Mexico; needle sharing;
D O I
10.1590/S0036-36342007000300001
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective. To estimate the prevalence of the hepatitis C virus (HCV) and HIV infection and associated risk behaviors among injection drug users (IDUs) in two northern Mexican cities. Material and Methods. Between February and April 2005, IDUs were recruited in Tijuana (N=222) and Ciudad Juarez (N=206) using respondent-driven sampling (RDS), a chain referral sampling approach. Interviewer-administered questionnaires assessed drug-using behaviors during the prior six months.Venous blood was collected for immunoassays to detect HIV and HCV antibodies. For HIV, Western blot or immunofluorescence assay was used for confirmatory testing. Final HCV antibody prevalence was estimated using RDS adjustments. Results. Overall, HCV and HIV prevalence was 96.0% and 2.8%, respectively, and was similar in both cities. Most IDUs (87.5%) reported passing on their used injection equipment to others, and 85.9% had received used equipment from others. Conclusions. HIV prevalence was relatively high given the prevalence of HIV in the general population, and HCV prevalence was extremely high among IDUs in Tijuana and Ciudad Juarez. Frequent sharing practices indicate a high potential for continued transmission for both infections. HCV counseling and testing for IDUs in Mexico and interventions to reduce sharing of injection equipment are needed.
引用
收藏
页码:165 / 172
页数:8
相关论文
共 50 条
  • [31] Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. (vol 42, pg 669, 2006)
    Hagan, H
    Latka, MH
    Campbell, JV
    Golub, ET
    Garfein, RS
    Thomas, DA
    Kapadia, F
    Strathdee, SA
    CLINICAL INFECTIOUS DISEASES, 2006, 42 (12) : 1818 - 1818
  • [32] Evolution of the prevalence of HIV infection and risk behavior of drug injection among HIV+ and HIV- drug users in three Spanish cities
    Portela, MJB
    Anta, GB
    de Hoz, LDF
    Morales, LR
    Gómez, CC
    Arenas, AR
    REVISTA CLINICA ESPANOLA, 2000, 200 (07): : 355 - 359
  • [33] Hepatitis C Virus Infection and Related Risk Factors among Injection Drug Users in Montenegro
    Bacak, Valerio
    Lausevic, Dragan
    Mugosa, Boban
    Vratnica, Zoran
    Terzic, Natasa
    EUROPEAN ADDICTION RESEARCH, 2013, 19 (02) : 68 - 73
  • [34] The importance of preventing hepatitis C virus infection among injection drug users in the United States
    Alter, MJ
    Moyer, LA
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 18 : S6 - S10
  • [35] Hepatitis C virus infection among injection drug users - Survival analysis of time to seroconversion
    Hagan, H
    Thiede, H
    Des Jarlais, DC
    EPIDEMIOLOGY, 2004, 15 (05) : 543 - 549
  • [36] Recommendations for the management of hepatitis C virus infection in injection drug users
    Grebely, Jason
    Robaeys, Geert
    Bruggmann, Philip
    Aghemo, Alessio
    Backmund, Markus
    Bruneau, Julie
    Byrne, Jude
    Dalgard, Olav
    Feld, Jordan J.
    Hellard, Margaret
    Hickman, Matthew
    Kautz, Achim
    Litwin, Alain
    Lloyd, Andrew R.
    Mauss, Stefan
    Prins, Maria
    Swan, Tracy
    Schaefer, Martin
    Taylor, Lynn E.
    Dore, Gregory J.
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2023, 111
  • [37] Acute hepatitis C virus infection in incarcerated injection drug users
    McGovern, Barbara H.
    Wurcel, Alysse
    Kim, Arthur Y.
    zur Wiesch, Julian Schulze
    Bica, Ioana
    Zaman, M. Tauheed
    Timm, Joerg
    Walker, Bruce D.
    Lauer, Georg M.
    CLINICAL INFECTIOUS DISEASES, 2006, 42 (12) : 1663 - 1670
  • [38] INFLUENCE OF F PROTEIN ON OUTCOME OF HEPATITIS C VIRUS INFECTION AMONG INJECTION DRUG USERS
    Wang Jie
    Zhang Yun
    Yang Jingjing
    Deng Xiaozhao
    Cao Min
    Yu Rongbin
    Xu Ke
    Wang Haopeng
    PROGRESS ON POST-GENOME TECHNOLOGIES AND MODERN NATURAL PRODUCTS, 2011, 2011, : 415 - 418
  • [39] Hepatitis C Virus Infection among Injection Drug Users with and without Human Immunodeficiency Virus Co-Infection
    Hsieh, Meng-Hsuan
    Tsai, Jih-Jin
    Hsieh, Ming-Yen
    Huang, Chung-Feng
    Yeh, Ming-Lun
    Yang, Jeng-Fu
    Chang, Ko
    Lin, Wei-Ru
    Lin, Chun-Yu
    Chen, Tun-Chieh
    Huang, Jee-Fu
    Dai, Chia-Yen
    Yu, Ming-Lung
    Chuang, Wan-Long
    PLOS ONE, 2014, 9 (04):
  • [40] Not all injection drug users are created equal: Heterogeneity of HIV, hepatitis C virus, and hepatitis B virus infection in Georgia
    Kuniholm, Mark H.
    Aladashvili, Malvina
    Del Rio, Carlos
    Stvilia, Ketavan
    Gabelia, Nino
    Chitale, Rohit A.
    Tsertsvadze, Tengiz
    Nelson, Kenrad E.
    SUBSTANCE USE & MISUSE, 2008, 43 (10) : 1424 - 1437